(Q37701647)

22 August 2017

1 reference

title

Role of palliative low-molecular-weight heparin for treating venous thromboembolism in patients with advanced cancer (English)

1 reference

22 August 2017

1 reference

venous thromboembolism

1 reference

Quy N H Tran

1

1 reference

22 August 2017

publication date

2 March 2010

1 reference

American Journal of Hospice and Palliative Medicine

22 August 2017

published in

1 reference

22 August 2017

volume

27

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

416-419

1 reference

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1049909110361244

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909110361244

Management of venous thromboembolism in patients with cancer: role of dalteparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909110361244

Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909110361244

Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909110361244

Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909110361244

Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909110361244

Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909110361244

Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909110361244

The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909110361244

Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909110361244

Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909110361244

21 January 2018

Identifiers

DOI

10.1177/1049909110361244

1 reference

22 August 2017

1 reference